An analysis published in the BMJ describing a "revolving door" between FDA and the biopharmaceutical industry has drawn a mix of reactions from experts, ranging from concerns about public perception to scorn of the report.
FDA-Industry Relations Faulted As 'Revolving Door' In BMJ Report
Academic authors say that more than half of FDA medical reviewers leave to either work or consult to industry; experts chime in with mixed reactions to the findings.